GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'

GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been ...
The Times Leader

New combination therapy for colorectal cancer, with University of Pittsburgh Medical Center involvement, lengthens survival

Many cancer types — breast, prostate, skin cancer — have 5-year survival rates and ample treatment options if caught early.
Richmond BizSense

Local startup Kinis pilots new fall prevention tech product, develops wearable tracker

After initially launching with a focus on footwear, a local startup is onto its next generation of products with an aim to help people stay on their feet.

Join Connect Biopharma’s Exclusive Live Investor Webinar and Q&A Session on November 3

ORLANDO, FLORIDA / ACCESS Newswire / October 30, 2025 / RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, Connect or the Company ...
The Lancet

The human crisis in cancer: a Lancet Oncology Commission

Amid unprecedented scientific progress in oncology, a growing body of evidence reveals a parallel and profound crisis in the ...